Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod-Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC).
Tjalf ZiemssenMarie GrothVeronika Eva WinkelmannTobias BoppPublished in: Vaccines (2023)
The antibody and T-cell responses support SARS-CoV-2 (booster) vaccines in siponimod-treated patients.